The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $226,253 Project Grant (CFDA 93.855, Allergy and Infectious Diseases Research) to The Washington University in St. Louis to conduct research on the role of the protein ADAM10 in modulating neutrophil-endothelial cell interactions during Staphylococcus aureus infections. The research aims to spatiotemporally analyze these early cellular and molecular interactions that shape the host response, with the potential to enable analysis of targeted ADAM10 therapy to improve outcomes. The project will run from January 2025 through December 2026. As a private research university with extensive federal R&D experience, Washington University will leverage its unique repository of transgenic mice, in vivo imaging capabilities, and microbiology tools to carry out this investigation into a common mechanism used by S. aureus to subvert the host immune response.
Generated 3/4/25, 6:42 AM